Claims
- 1. A method for inhibiting cancer cell growth or killing cancer cells comprising eliciting an immune response with an immunologically effective amount of a composition comprising a phosphatidylserine/polypeptide conjugate.
- 2. The method of claim 1, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.
- 3. The method of claim 1, wherein said cancer cell is comprised within an animal.
- 4. The method of claim 3, wherein said animal is a human.
- 5. The method of claim 1, wherein said composition further comprises a pharmaceutical excipient.
- 6. The method of claim 5, wherein said composition is administered to said human topically, parenterally, orally, subcutaneously, or by direct injection into a tissue site.
- 7. The method of claim 1, wherein said polypeptide is selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β2-glycoprotein I.
- 8. The method of claim 7, wherein said polypeptide is β2-glycoprotein I.
- 9. A method for treating cancer comprising eliciting an immune response with an immunologically effective amount of a composition comprising a phosphatidylserinel polypeptide conjugate.
- 10. A method for treating cancer comprising contacting a subject with a lipid or lipid/polypeptide conjugate effective to treat said cancer.
- 11. The method of claim 8, wherein said lipid is phosphatidylcholine or phosphatidylserine.
- 12. A method of generating an immune response, comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate composition.
- 13. A method of making an antibody that specifically binds to phosphatidylserine, a phosphatidylcholine/polypeptide conjugate or a phosphatidylserine/polypeptide conjugate, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate composition.
- 14. The method of claim 13, wherein a composition comprising phosphatidylserine/BSA, phosphatidylserine/KLH, phosphatidylserine/BGG, or phosphatidylserine/β2-glycoprotein I conjugate is administered to the animal.
- 15. An antibody that specifically binds to phosphatidylserine a phosphatidylcholine/polypeptide conjugate or a phosphatidylserine/polypeptide conjugate, said antibody made by a process comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate composition.
- 16. The antibody of claim 15, wherein a composition comprising phosphatidylserine/BSA, phosphatidylserine/KLH, phosphatidylserine/BGG, or phosphatidylserine/β2-glycoprotein I conjugate is administered to the animal
- 17. The antibody of claim 16, wherein said polypeptide is β2-glycoprotein I.
- 18. The antibody of claim 15, wherein the antibody is linked to a detectable label.
- 19. The antibody of claim 18, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.
- 20. The antibody of claim 18, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.
- 21. The antibody of claim 15, wherein the antibody is a monoclonal antibody.
- 22. A method for detecting a phosphatidylserine, phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate in a biological sample, comprising the steps of:
(a) obtaining a biological sample suspected of containing a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate; (b) contacting said sample with a first antibody that binds to a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate, under conditions effective to allow the formation of immune complexes; and (c) detecting the immune complexes so formed.
- 23. An immunodetection kit comprising, in suitable container means, an antibody that specifically binds to phosphatidylserine or to a phosphatidylserine/polypeptide conjugate, and an immunodetection reagent.
- 24. The immunodetection kit of claim 23, wherein the immunodetection reagent is a detectable label that is linked to said conjugate or said antibody.
- 25. The immunodetection kit of claim 23, wherein the immunodetection reagent is a detectable label that is linked to a second antibody that has binding affinity for said conjugate or said first antibody.
- 26. A method for treating cancer in an animal comprising generating in said animal an immune response to a composition comprising a phosphatidylserine or phosphatidylserine/polypeptide conjugate effective to treat said cancer.
- 27. The method of claim 26, wherein the composition comprises a phosphatidylserine/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β2-glycoprotein I.
Parent Case Info
[0001] The present application is a continuation-in-part of U.S. Provisional Patent Application Serial No. 60/071,794 filed Dec. 31, 1997. The entire text of the above-referenced disclosure is specifically incorporated by reference herein without disclaimer.
Government Interests
[0002] The United States has certain rights in the present invention pursuant to Grant DK41714 from the National Institutes of Health.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60071794 |
Dec 1997 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09224558 |
Dec 1998 |
US |
Child |
09974753 |
Oct 2001 |
US |